Home > Authorities > Grants > Record #207621 > print

001     207621
005     20230212173758.0
024 7 _ |a G:(EU-Grant)765269
|d 765269
|2 CORDIS
024 7 _ |a G:(EU-Call)H2020-MSCA-ITN-2017
|d H2020-MSCA-ITN-2017
|2 CORDIS
024 7 _ |a corda__h2020::765269
|2 originalID
035 _ _ |a G:(EU-Grant)765269
150 _ _ |a Improving Genome Editing Efficiency (IMGENE)
|y 2017-09-01 - 2021-08-31
371 _ _ |a INSTITUTO DE BIOLOGIA MOLECULAR E CELULAR-IBMC
|d Portugal
|e http://www.ibmc.up.pt
|v CORDIS
371 _ _ |a MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (MDC)
|b MDC
|d Germany
|e http://www.mdc-berlin.de
|v CORDIS
371 _ _ |a IT University of Copenhagen
|b IT University of Copenhagen
|d Denmark
|e http://en.itu.dk/
|v CORDIS
371 _ _ |a ACADEMISCH ZIEKENHUIS LEIDEN
|b Leiden University Medical Center
|d Netherlands
|e http://www.lumc.nl
|v CORDIS
371 _ _ |a ASTRAZENECA AB
|d Sweden
|e http://www.astrazeneca.com
|v CORDIS
371 _ _ |a USTAV MOLEKULARNI GENETIKY AKADEMIE VED CESKE REPUBLIKY VEREJNA VYZKUMNA INSTITUCE
|b UMG AV CR, v. v. i.
|d Czech Republic
|e http://www.img.cas.cz
|v CORDIS
371 _ _ |a UNIVERSITAETSKLINIKUM FREIBURG
|b UKLFR
|d Germany
|e http://www.uniklinik-freiburg.de/ip/splash/start.html
|v CORDIS
372 _ _ |a H2020-MSCA-ITN-2017
|s 2017-09-01
|t 2021-08-31
450 _ _ |a IMGENE
|w d
|y 2017-09-01 - 2021-08-31
510 1 _ |0 I:(DE-588b)5098525-5
|a European Union
|2 CORDIS
680 _ _ |a CRISPR genome editing technology is considered to become the greatest technological improvement in biomedical research since the invention of the polymerase chain reaction 25 years ago and pharmaceutical companies as well as academic research are eager to apply it. However, the efficiency of introducing defined changes into the genome by CRISPR is still low, currently limiting its application in basic research, industry and gene therapy. IMGENE unites expert European research groups of academia and industry to address by innovative and complementary approaches the low efficiency of precise genome editing using CRISPR technology. To our best knowledge, IMGENE is the only concerted approach to tackle the important problem of low genome editing efficiency of CRISPR in a multidisciplinary, intersectorial manner. The IMGENE consortium consisting of 6 academic and 1 industrial beneficiary (AstraZeneca), 2 industrial partners (Taconic; MilliporeSigma), and the patient organization Genetic Alliance, aims to improve the genome editing efficiency of CRISPR by research training of 8 ESRs to unleash the full potential of this technology. Combining complementary knowledge on protein chemistry, molecular biology, cellular biology, viral vectors, transgenic mice, gene therapy, and bioinformatics present in the network, IMGENE will establish novel tools and protocols for improved CRISPR genome editing efficiency that will be of immediate benefit for health and life science research, the pharmaceutical industry, and the application of gene therapy. In addition, IMGENE addresses crucial ethical questions related to the application of genome editing technology in animals, plants, and humans, which have to be solved to gain acceptance by the society. By excellent research training of 8 ESRs on a scientifically and economically highly relevant topic and additional training in transferable skills, IMGENE will educate novel leaders with great career perspectives in industry and academia.
909 C O |o oai:juser.fz-juelich.de:839501
|p authority:GRANT
|p authority
909 C O |o oai:juser.fz-juelich.de:839501
970 _ _ |a oai:dnet:corda__h2020::b09a165093e32d1122714901d1899824
980 _ _ |a G
980 _ _ |a CORDIS
980 _ _ |a AUTHORITY

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21